Over 2300 Total Lots Up For Auction at Five Locations - FL 09/28, OK 09/29, NJ Cleansweep 09/30, CA 10/01, NJ 10/05

Lucida Medical receives CE marking for Pi, its AI-machine learning software for detecting prostate cancer from MR

Press releases may be edited for formatting or style | June 02, 2021 Artificial Intelligence MRI

Co-founder and Chief Medical Officer Prof Evis Sala, Professor of Oncological Imaging at the University of Cambridge, said:

“We are tremendously excited about this system and its potential to enhance our ability to detect cancer accurately and early. Now Pi™ has CE marking, we can look forward to working with hospitals and radiology and urology partners to bring it into clinical use. Covid-19 has created a serious backlog in cancer screening and Lucida Medical is well placed to help us clear this and further improve the care that we offer over the coming years.”

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.


Dr Antony Rix, CEO and Co-founder, said:

“Today, about half of cancers are found when they have already spread and this makes them difficult and costly to treat. Our unique approach could allow patients to get exactly the tests, diagnosis and treatment that they need. With around 20 million new cases of cancer diagnosed each year worldwide, there is enormous potential for us to improve patients’ outcomes and reduce costs for health systems like the NHS.”

Professor Anwar Padhani, Professor of Cancer Imaging at the Institute of Cancer Research in London said:

“AI is going to be essential to successfully deploy community-wide MRI-driven prostate cancer diagnosis. AI system will enable the main benefits of biopsy avoidance are delivered while decreasing the variations in biopsy yields. Initial uses will be to support radiologists’ workflow including gland and target outlining tasks for fusion biopsies. Developing AI systems as clinical decision-making tools requires further efforts. The CE mark enables us to take the next steps”

Professor Padhani is an internationally recognized Oncological MRI radiologist and the clinical lead in MRI at the Paul Strickland Scanner Centre.

Professor Hashim Ahmed, Professor of Urology at Imperial College, University of London said:

“There is tremendous need for an AI decision support system that significantly increases productivity and the quality of MR prostate cancer reporting and the Lucida Medical system shows great promise”

Professor Ahmed was one of the very early users of MRI and transperineal biopsy to diagnose prostate cancer. Further he is a pioneer of focal therapy treatment for prostate cancer. His current trials are focused on the Prostagram, the objective being to have a short MRI scan to screen for prostate cancer in the same way as mammograms are used to screen for breast cancer in women.

Oliver Kemp, CEO of Prostate Cancer Research, said: “Prostate cancer patients deserve the best possible care and to live as full a life as possible. We are delighted that our investment has helped take this exciting technology through regulatory approvals. We are looking forward to seeing the benefits for prostate cancer patients and the NHS.

You Must Be Logged In To Post A Comment